Measles in Dangerous in Adults: Who and How to Assess for the MMR Booster

GSK is partnering with the UK Dementia Research Institute and Health Data Research UK to further investigate the potential for the RZV vaccine to mitigate cognitive decline.

In individuals with skin of color with AD, lebrikizumab was associated with improved QoL and importantly with high rates of patient-reported treatment satisfaction.

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

The impact of childhood onset AD on adult psychosocial experience is far reaching and profound according to findings from the Scars of Life Survey.

According to the CDC, influenza is responsible for 33 million illnesses, 430,000 hospitalizations, and 19,000 deaths so far this season.

CDC midseason data suggest low COVID-19 vaccine efficacy in adults aged 18 to 64 years, with somewhat better impact on those aged 65 years and older.